Core Viewpoint - Luye Pharma Group's subsidiary, Shandong Luye Pharmaceutical Co., Ltd., plans to transfer 38.5 million H-shares of Boan Biotechnology to Luye Geneora Holding Limited by January 22, 2026, as part of a subscription agreement related to exchangeable preferred shares [1]. Group 1 - Boan Biotechnology's stock price increased by 3.31% to HKD 9.04, with a trading volume of HKD 365 million [1]. - Luye Pharma previously acquired 98% of Boan Biotechnology, integrating it into its system to access its antibody drug pipeline, technology platform, and production assets [1]. - By 2025, Shandong Luye Pharmaceutical Co., Ltd. is expected to hold 70.81% of Boan Biotechnology's shares, positioning Boan as a key vehicle for Luye Pharma's transition from traditional small molecules to biopharmaceuticals [1].
博安生物现涨超3% 山东绿叶制药拟向Luye Geneora Holding进一步转让公司H股